Annual Innovation and Collaboration Conference Focuses on the Glycemic Management Journey and Providing Education for Health Systems to Improve Patient Safety and Outcomes
WALTHAM, Mass. (July 26, 2023) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the details surrounding its annual conference on glycemic innovation and collaboration, “Time to Target: The Glycemic Management Journey.” Attendees of this year’s event will explore the importance of prioritizing inpatient glycemic management and receive prescriptive guidance on how to assemble the right people, create processes that support quality improvement and leverage technology to achieve success in their health system. There is no cost to attend the conference, which will be held virtually on October 25-26, 2023.
“Time to Target is an invaluable resource for everyone working in healthcare because of its spotlight on inpatient glycemic management - a critical topic often underrepresented at other national conferences,” said Dr. Andjela Drincic, Professor, Division of Diabetes, Endocrinology & Metabolism at University of Nebraska Medical Center. “This is a uniquely accessible and educational conference. The programming is exceptional and engaging all the while being free and available online so that anyone can learn from anywhere.”
There are 529 million people worldwide currently living with diabetes, including more than 37 million in the United States. A recent study revealed that number is projected to more than double in the next three decades and surpass 1.3 billion globally by 2050. Glycemic management challenges extend beyond people living with diabetes, cutting across disease states and reasons for admission and impacting every hospital department. While 10% of Americans live with diabetes, nearly 40% of all hospitalized patients require insulin therapy to regulate high blood sugar during their stay. Hyperglycemia often occurs in patients after surgery due to complex pathophysiology and the body’s response to stress. This is exacerbated by the fact hundreds of medications impact blood glucose and can even cause insulin resistance.
Decades of research have shown that inadequate inpatient glycemic management can lead to longer lengths of stay, higher readmission rates, increased costs for patients and healthcare systems, and greater rates of morbidity and mortality. While hospitals and health systems nationwide are at various stages of optimizing their glycemic management programs, there is a sense of urgency within the industry to make marked improvements after the Centers for Medicare & Medicaid Services (CMS) introduced two eCQMs that center on rates of hyper- and hypoglycemia. As hospitals prepare to report on these metrics in the coming months, Glytec’s annual event aims to educate health systems on how to develop evidence-based best practices, overcome institutional roadblocks, and foster a culture of innovation and collaboration.
“At a time when glycemic management has reached its tipping point at health systems across the country, Time to Target has emerged as a valuable resource for those committed to improving patient safety and outcomes,” said John Downey, Chief Commercial Officer at Glytec. “Since its inception, this conference has brought together hospital leaders, providers, clinicians and more to discuss the current state of insulin management and identify opportunities to establish and improve best practices. We’re proud to have Glytec customers speak at this event each year because their guidance and successes underpin the evolution of the industry. Now, in its third year, Time to Target will continue its collaborative approach to move the industry forward and usher in the next generation of glycemic management.”
Time to Target sessions will consist of live interactive panel discussions, keynote presentations from industry experts and data-driven case studies that cover topics such as inpatient glycemic management pearls, overcoming clinical inertia and quality improvement initiatives. Featured speakers include:
- Dr. Guillermo E. Umpierrez, Chief of Diabetes and Endocrinology at Grady Health Systems
- Dr. Andjela Drincic, Professor, Division of Diabetes, Endocrinology & Metabolism at University of Nebraska Medical Center
- Dr. Gregory Maynard, Chief Quality Officer at University of California, Davis Medical Center
- Dr. Preetham Talari, Vice President of Clinical Transformation & Outcomes Optimization at Ballad Health
- Dr. Roma Gianchandani, Medical Director, Diabetes Quality at Cedars-Sinai
All Time to Target sessions will be available on-demand through December 31, 2023. For more information about the event, including the agenda, a list of confirmed speakers and registration details, visit https://www.glytectimetotarget.com/.
About Glytec
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) and LinkedIn, or visit www.GlytecSystems.com.
Contact
Geoff Lopes
fama PR for Glytec
Glytec@famapr.com
SOP-34